EU enlargement

The European Medicines Agency (EMA) takes part in projects to foster links with European Union (EU) enlargement countries, to lay the foundations of future co-operation in EMA's networks.
CorporateGovernance

EMA's projects in the area of EU enlargement fall within the assistance programmes launched by the European Commission to support pre-accession activities for countries wishing to join the EU. 

Countries with the membership status of candidates are:

Additionally, Kosovo is a potential candidate.

Instrument for Pre-accession Assistance

The European Commission's Instrument for Pre-accession Assistance (IPA) programme supports the participation of enlargement countries in the work of selected EU agencies.

EMA activities under the IPA programme aim to build working relationships with the beneficiary national competent authorities, to prepare for their future collaboration in the European medicines regulatory network.

To achieve this aim, the programme offers assistance to beneficiary national competent authorities in aligning their standards and practices with those established in the EU and contributes to the creation of communication and information exchange systems that enable their effective participation in the networks of the EU regulatory system.

Programme activities include the below:

  • Organising ad hoc conferences and training sessions to exchange views, explain the EU legal framework and identify areas for action
  • Assisting beneficiary countries with participating in EMA meetings and training courses as observers
  • Providing beneficiary countries with access to selected e-learning modules in the EU Network Training Centre (EU NTC)

For more details on the IPA programme, see European Commission: Overview - Instrument for Pre-accession Assistance.

EMA's participation in the IPA programme for 2024-26

EMA and the European medicines regulatory network continue to cooperate with beneficiary countries through a set of activities established in the project ‘EU4 alignment on medicines regulation in the Western Balkans and Türkiye’.

Current beneficiaries include:

  • Albania
  • Bosnia and Herzegovina
  • Kosovo
  • Montenegro
  • North Macedonia
  • Serbia
  • Türkiye

Kosovo's designation as a current beneficiary is without prejudice to positions on status and is in line with UNSCR 1244 and the ICJ Opinion on the Kosovo Declaration of Independence.

Moldova, Georgia and Ukraine also take part of the program initiatives

Planned activities for beneficiaries include:

The European Commission's Directorate-General for Neighbourhood and Enlargement Negotiations (DG NEAR) provides funding under the third extension of the IPA programme (IPA III).

The project started in January 2024 and covers activities until 2026.

Training events under the Instrument of Pre-accession Assistance

Hands-on training to strengthen regulatory capacity in candidate countries

From 2 to 3 October, EMA held an in-person training simulating real Committee for Medicinal Products for Human Use (CHMP) assessments.

Assessors from national competent authorities in beneficiary countries took part in the event. They represented the following countries:

  • Albania
  • Bosnia and Herzegovina
  • Kosovo
  • Montenegro
  • North Macedonia
  • Serbia
  • Ukraine

The Institute for Medicines and Medical Devices of Montenegro (CiNMED) hosted the event. This was the first time that a candidate country hosted an annual assessors training.

For more information, see:

The full agenda of the event is available below:

Agenda - Instrument for Pre-accession Assistance (IPA) training on assessing medicinal products in the EU: A practical introduction

English (EN) (246.23 KB - PDF)

First published:
View

Other IPA training events

Select the expandable panel below to find information on previous EMA trainings held under the IPA programme.

Share this page